In the global pharmaceutical industry, GMP compliance is not just a regulatory requirement—it’s the foundation of product safety and market access. For biotech and nutraceutical enterprises, non-compliant freeze-drying processes can lead to costly delays, batch rejections, and even market bans. Since 2009, Lyomac has been a trusted partner in navigating these complexities, delivering over 200 GMP/FDA/GAMP5-compliant freeze-drying systems across 15+ countries.
In the biopharmaceutical and vaccine sectors, freeze-drying technology is the critical barrier to preserving drug activity and stability. Over 60% of biological products rely on lyophilization for global distribution, yet temperature fluctuations, inconsistent vacuum levels, or sterile control gaps often lead to costly batch failures. Since 2009, Zhejiang Lyomac Pharmaceutical Equipment Co., Ltd. has transformed this challenge into an opportunity, turning freeze-drying from an experience-driven process into a data-backed precision solution.
